Specific gene therapy targeting EEF1A2 using clustered regularly interspaced short palindromic repeats (CRISPR) or an anti-EEF1A2 peptide can be designed to target EEF1A2 interactions, which can hinder the tumorigenesis property of cancer. Here, EEF1A2 is linked to cancer.